71 related articles for article (PubMed ID: 20029687)
1. [Relevance of vasoactive intestinal peptide and total bronchial mucin in rat lung.].
Li X; Wang XM; Zhang JS
Sheng Li Xue Bao; 2009 Dec; 61(6):539-43. PubMed ID: 20029687
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide stimulates mucus secretion, but nitric oxide has no effect on mucus secretion in the ferret trachea.
Kim JS; Okamoto K; Arima S; Rubin BK
J Appl Physiol (1985); 2006 Aug; 101(2):486-91. PubMed ID: 16645189
[TBL] [Abstract][Full Text] [Related]
3. Temporal and spatial distribution of VIP, CGRP and their receptors in the development of airway hyperresponsiveness in the lungs.
Ren YH; Qin XQ; Guan CX; Luo ZQ; Zhang CQ; Sun XH
Sheng Li Xue Bao; 2004 Apr; 56(2):137-46. PubMed ID: 15127121
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide-stimulated glycoconjugate secretion from conjunctival goblet cells.
Dartt DA; Kessler TL; Chung EH; Zieske JD
Exp Eye Res; 1996 Jul; 63(1):27-34. PubMed ID: 8983961
[TBL] [Abstract][Full Text] [Related]
5. [A clinical study on determination of plasma vasoactive intestinal peptide and the relationship between plasma vasoactive intestinal peptide and bronchial responsiveness in asthmatics].
Liu A; Li PS; Zhang ZJ
Zhonghua Nei Ke Za Zhi; 1993 Mar; 32(3):165-6. PubMed ID: 8222979
[TBL] [Abstract][Full Text] [Related]
6. [The temporal and spatial distribution of vasoactive intestinal peptide and its receptor in the development of airway hyperresponsiveness].
Ren YH; Qin XQ; Guan CX; Luo ZQ; Zhang CQ; Sun XH
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):224-8. PubMed ID: 15144609
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of extended lung preservation with a vasoactive intestinal peptide-enriched University of Wisconsin solution.
Alessandrini F; Sasaki S; Said SI; Lodi R; LoCicero J
Transplantation; 1995 May; 59(9):1253-8. PubMed ID: 7762057
[TBL] [Abstract][Full Text] [Related]
8. Functional antagonism between hormone receptor systems: modulation of glycoprotein secretion in secretory epithelial cells.
Amin DN; Goswami S; Klein T; Maayani S; Marom Z
Am J Respir Cell Mol Biol; 1991 Feb; 4(2):135-9. PubMed ID: 1671333
[TBL] [Abstract][Full Text] [Related]
9. Age-related changes in vasoactive intestinal polypeptide levels and distribution in the rat lung.
Geppetti P; De Rossi M; Mione MC; Renzi D; Amenta F
J Neural Transm; 1988; 74(1):1-10. PubMed ID: 3171570
[TBL] [Abstract][Full Text] [Related]
10. Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.
Onoue S; Misaka S; Aoki Y; Karaki S; Kuwahara A; Ohide A; Mizumoto T; Yamada S
Eur J Pharm Sci; 2010 Nov; 41(3-4):508-14. PubMed ID: 20797433
[TBL] [Abstract][Full Text] [Related]
11. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
Groneberg DA; Rabe KF; Fischer A
Eur J Pharmacol; 2006 Mar; 533(1-3):182-94. PubMed ID: 16473346
[TBL] [Abstract][Full Text] [Related]
12. Activation of CFTR trafficking and gating by vasoactive intestinal peptide in human bronchial epithelial cells.
Qu F; Liu HJ; Xiang Y; Tan YR; Liu C; Zhu XL; Qin XQ
J Cell Biochem; 2011 Mar; 112(3):902-8. PubMed ID: 21328463
[TBL] [Abstract][Full Text] [Related]
13. The respiratory effects of neuropeptides.
Joos G; Kips J; Pauwels R; Van der Straeten M
Eur J Respir Dis Suppl; 1986; 144():107-36. PubMed ID: 2427352
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells.
Guan CX; Zhang M; Qin XQ; Cui YR; Luo ZQ; Bai HB; Fang X
Peptides; 2006 Dec; 27(12):3107-14. PubMed ID: 16965837
[TBL] [Abstract][Full Text] [Related]
15. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
[TBL] [Abstract][Full Text] [Related]
16. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
[TBL] [Abstract][Full Text] [Related]
17. [Effect of vasoactive intestinal peptide and epidermal growth factor on the adhesion of eosinophils to bronchial epithelial cells].
Li X; Xing XM; Zhang JS; Tan YR
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):772-5, 781. PubMed ID: 17062950
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.
Hokari R; Lee H; Crawley SC; Yang SC; Gum JR; Miura S; Kim YS
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G949-59. PubMed ID: 16227528
[TBL] [Abstract][Full Text] [Related]
19. [Effects of vasoactive intestinal peptide on chemotaxis of bronchial epithelial cells].
Guan CX; Zhang CQ; Qin XQ; Luo ZQ; Zhou FW; Sun XH
Sheng Li Xue Bao; 2002 Apr; 54(2):103-6. PubMed ID: 11973586
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation.
Juarranz MG; Bodega G; Prieto JC; Guijarro LG
Prostate; 2001 Jun; 47(4):285-92. PubMed ID: 11398176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
